Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

NEW YORK, Jan. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

http://www.reportlinker.com/p0357279/Emerging-Opportunities-in-Biosimilar-and-Biobetter-Drugs-Markets.html

Executive Summary

The biosimilar and biobetter drugs market has started to position itself in a grand manner following a series of changes in regulatory framework in many countries. The biosimilar market segment represents a host of opportunities to the generics manufacturers to enter in a market, which is largely driven by commands premium prices and unmet needs. Backed by this feature, the market is continuing to outperform the global pharmaceutical market. "Emerging Opportunities in Biosimilar and Biobetter Drugs Markets" provides a detailed overview and a succinct, but deep-dive analysis on the biosimilar and biobetter drugs segments. The report discusses various exclusive features of biobetter drugs and studies their importance in meeting the future demand. It also highlights various emerging trends in the market and relates these with the future market growth.

The key objective of this report is to identify and probe into the emerging opportunities in the biobetter and biosimilar drugs market. It also tries to estimate the opportunities in various biological drugs segments including monoclonal antibodies, Erythropoietin and insulin, thus giving a complete idea about the market dynamics to the target audience of this report.

The report Emerging Opportunities in Biosimilar and Biobetter Drugs Markets also includes information on the key players in the industry and their product portfolio. This will enable the target audience of this report in understanding the contemporary industry scenario. Besides, the report gives complete information on various products whose patents are on the verge of expiration and thus, it is offering huge opportunities for generics manufacturers. Some of the key findings of report are given below:

  • The clause of "12 Year Exclusivity" for biologics in the US healthcare reform bill is going to have a long term impact on the growth of biosimilar drugs market
  • The increasing application of monoclonal antibodies in the cancer treatment is going to boost the demand of biosimilar and biobetter drugs in this market segment

Delivery Time

Three Business days

To order this report:

: Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”